Effect of light and diurnal variation on macular thickness in X-linked retinoschisis: a case series.
Diurnal variation
RS1
X-linked retinoschisis
XLRS
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
26
09
2019
accepted:
18
12
2019
revised:
07
12
2019
pubmed:
4
1
2020
medline:
31
12
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
Diurnal variations in foveal thickness have been reported in several ocular pathologies including X-linked retinoschisis (XLRS), but its underlying mechanism is poorly understood. Rods are active under scotopic conditions with high metabolic demand, and its decrease may have positive effect on metabolic activity and macular thickness. The purpose of this study is to evaluate whether exposure to light and diurnal variation influence macular thickness in XLRS patients. Five patients with clinical suspicion of XLRS underwent RS1 gene sequencing and optical coherence tomography measurements at three consecutive times: morning following sleep in a dark room, morning following sleep in an illuminated room, and late afternoon following sleep in an illuminated room. Central macular thickness (CMT) was compared between measurements, and molecular analysis was performed. Five RS1 mutations were identified: p.Gly140Arg, p.Arg141Cys, p.Gly109Glu, p.Pro193Leu, and p.Arg200His in patients 1-5, respectively. Two patients (4-5) had atrophied macula and were excluded from macular thickness variation analysis. A significant decrease in CMT between morning and afternoon measurements was observed in all patients (1-3: mean: 455.0 ± 32 μm to 342.17 ± 39 μm, 25%). Morning measurements following sleep in an illuminated room show a CMT reduction in all eyes of all patients with a mean reduction of 113 μm (mean: 547.17 ± 105 μm to 455.0 ± 32 μm, 17%). Among XLRS patients, CMT decreased at the afternoon compared to the morning of the same day and may be reduced following sleep in an illuminated room. These results help shed light on the pathophysiologic process underlying intraretinal fluid accumulation involved with the disease.
Sections du résumé
BACKGROUND
BACKGROUND
Diurnal variations in foveal thickness have been reported in several ocular pathologies including X-linked retinoschisis (XLRS), but its underlying mechanism is poorly understood. Rods are active under scotopic conditions with high metabolic demand, and its decrease may have positive effect on metabolic activity and macular thickness. The purpose of this study is to evaluate whether exposure to light and diurnal variation influence macular thickness in XLRS patients.
METHODS
METHODS
Five patients with clinical suspicion of XLRS underwent RS1 gene sequencing and optical coherence tomography measurements at three consecutive times: morning following sleep in a dark room, morning following sleep in an illuminated room, and late afternoon following sleep in an illuminated room. Central macular thickness (CMT) was compared between measurements, and molecular analysis was performed.
RESULTS
RESULTS
Five RS1 mutations were identified: p.Gly140Arg, p.Arg141Cys, p.Gly109Glu, p.Pro193Leu, and p.Arg200His in patients 1-5, respectively. Two patients (4-5) had atrophied macula and were excluded from macular thickness variation analysis. A significant decrease in CMT between morning and afternoon measurements was observed in all patients (1-3: mean: 455.0 ± 32 μm to 342.17 ± 39 μm, 25%). Morning measurements following sleep in an illuminated room show a CMT reduction in all eyes of all patients with a mean reduction of 113 μm (mean: 547.17 ± 105 μm to 455.0 ± 32 μm, 17%).
CONCLUSIONS
CONCLUSIONS
Among XLRS patients, CMT decreased at the afternoon compared to the morning of the same day and may be reduced following sleep in an illuminated room. These results help shed light on the pathophysiologic process underlying intraretinal fluid accumulation involved with the disease.
Identifiants
pubmed: 31897705
doi: 10.1007/s00417-019-04578-7
pii: 10.1007/s00417-019-04578-7
doi:
Substances chimiques
Eye Proteins
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-536Subventions
Organisme : Office of the Chief Scientist, Ministry of Health
ID : 7205
Références
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2313-6
pubmed: 15980216
Br J Ophthalmol. 2005 Jun;89(6):764-9
pubmed: 15923516
Hum Mutat. 1999;13(4):338
pubmed: 10220153
Trials. 2014 Nov 22;15:458
pubmed: 25417120
Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a017368
pubmed: 26101206
Eye (Lond). 2010 Jul;24(7):1149-55
pubmed: 20139913
Curr Biol. 2008 Dec 23;18(24):1917-21
pubmed: 19084410
Surv Ophthalmol. 2004 Mar-Apr;49(2):214-30
pubmed: 14998693
Nat Genet. 1997 Oct;17(2):164-70
pubmed: 9326935
Br J Ophthalmol. 2001 Mar;85(3):366-70
pubmed: 11222350
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):617-24
pubmed: 14744906
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):112-9
pubmed: 7507905
Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):593-6
pubmed: 19052771
Vis Neurosci. 2006 May-Aug;23(3-4):651-61
pubmed: 16962009
Eye (Lond). 2011 Dec;25(12):1546-54
pubmed: 22020171
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3318-23
pubmed: 17591904
Ophthalmology. 2004 Feb;111(2):211-7
pubmed: 15019364
Hum Mol Genet. 1998 Jul;7(7):1185-92
pubmed: 9618178
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4707-11
pubmed: 16303968
Ophthalmology. 2014 Mar;121(3):802-3.e3
pubmed: 24309554
Ophthalmic Genet. 2018 Aug;39(4):437-442
pubmed: 29902095
Eye (Lond). 1997;11 ( Pt 6):872-5
pubmed: 9537150
Transl Vis Sci Technol. 2019 Jul 18;8(4):7
pubmed: 31360613